Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||CC-122 + Cyclophosphamide + Prednisone + Rituximab + Vincristine|
|Synonyms||CC-122 + R-CHOP|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CC-122||Avadomide||Avadomide (CC-122) is an immunomodulatory drug analog that targets Cereblon and promotes degradation of several proteins, including Ikaros and Aiolos, leading to decreased B-cell proliferation and decreased tumor angiogenesis (Blood Dec 2014, 124 (21) 3500).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Prednisone||Adasone||Dehydrocortisone||Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 6||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, and in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia (FDA.gov).|
|Vincristine||Oncovin||22-Oxovincaleukoblastine||Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03283202||Phase Ib/II||CC-122 + Cyclophosphamide + Prednisone + Rituximab + Vincristine||Study of Safety and Efficacy of CC-122 Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors||Active, not recruiting|